Pembrolizumab
Merck
['melanoma']
 this is a pretty striking result in terms of event-free survival at the two-year landmark. i think this is a nice trial with a simple, but powerful design, said dr. james larkin, who was also a discussant for the #esmo22 #melanoma session. 
OBR is an oncology-focused digital media company that provides news and information resources to oncology professionals.